We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
ADME LIMS will Accelerate data Reporting at QPS
Product News

ADME LIMS will Accelerate data Reporting at QPS

ADME LIMS will Accelerate data Reporting at QPS
Product News

ADME LIMS will Accelerate data Reporting at QPS


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "ADME LIMS will Accelerate data Reporting at QPS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy


Ben Chien, PHD, QPS chairman, president and CEO, said: "Studies determining ADME patterns in laboratory animals and humans are an integral part of our drug metabolisn and pharmacokinetic services and, as a quality initiative, we have been actively integrating radio-labelled mass balance/excretion and tissue distribution by Quantitative Whole-Body Autoradiography under one study protocol. This allows us to start on the companion metabolite profiling and identification studies in a shorter time frame.
 
"The addition of Debra will increase our competitive advantage and allow us to report high quality data to our sponsors even more quickly."
 
Huw Loaring, systems director at LabLogic, added: "Contract research organisations (CROs) are seeing big returns from the time savings achieved using Debra for their ADME studies, especially in terms of reporting and data checking.
 
"Increasingly, many pharmaceutical customers are using turnkey ADME solution providers like QPS - not just for their in vivo studies, but also for radiochromatography on their samples and the ensuing determination of key metabolites.
 
"We are excited by the new tools coming early next year to allow CROs to share data back to their sponsors, which will allow them to understand the human biotransformation pathways of their drug candidates at a very early stage of development. The latter is extremely important, not only in terms of identifying MIST-triggering metabolites but also because it supports bio-waiver applications."

Advertisement